Homologous peptides derived from influenza A, B and C viruses induce variable CD8+ T cell responses with cross-reactive potential

Andrea T. Nguyen, Hiu Ming Peter Lau, Hannah Sloane, Dhilshan Jayasinghe, Nicole A. Mifsud, Demetra S.M. Chatzileontiadou, Emma J. Grant, Christopher Szeto, Stephanie Gras

Research output: Contribution to journalArticleResearchpeer-review

11 Citations (Scopus)

Abstract

Objective: Influenza A, B and C viruses (IAV, IBV and ICV, respectively) circulate globally, infecting humans and causing widespread morbidity and mortality. Here, we investigate the T cell response towards an immunodominant IAV epitope, NP265-273, and its IBV and ICV homologues, presented by HLA-A*03:01 molecule expressed in ~ 4% of the global population (~ 300 million people). Methods: We assessed the magnitude (tetramer staining) and quality of the CD8+ T cell response (intracellular cytokine staining) towards NP265-IAV and described the T cell receptor (TCR) repertoire used to recognise this immunodominant epitope. We next assessed the immunogenicity of NP265-IAV homologue peptides from IBV and ICV and the ability of CD8+ T cells to cross-react towards these homologous peptides. Furthermore, we determined the structures of NP265-IAV and NP323-IBV peptides in complex with HLA-A*03:01 by X-ray crystallography. Results: Our study provides a detailed characterisation of the CD8+ T cell response towards NP265-IAV and its IBV and ICV homologues. The data revealed a diverse repertoire for NP265-IAV that is associated with superior anti-viral protection. Evidence of cross-reactivity between the three different influenza virus strain-derived epitopes was observed, indicating the discovery of a potential vaccination target that is broad enough to cover all three influenza strains. Conclusion: We show that while there is a potential to cross-protect against distinct influenza virus lineages, the T cell response was stronger against the IAV peptide than IBV or ICV, which is an important consideration when choosing targets for future vaccine design.

Original languageEnglish
Article numbere1422
Number of pages17
JournalClinical & Translational Immunology
Volume11
Issue number10
DOIs
Publication statusPublished - 2022

Keywords

  • CD8 T cell
  • cross-reactivity
  • HLA
  • immune response
  • immunodominant epitope
  • Influenza

Cite this